Clinical Significance of TIPE2 Protein Upregulation in Non-Hodgkin's Lymphoma

被引：12
作者：
Hao, Chunyan [2 ]
Zhang, Na [1 ]
Geng, Minghong [1 ,4 ]
Ren, Qing [5 ]
Li, Yan [1 ]
Wang, Yan [2 ]
Chen, Youhai H. [3 ]
Liu, Suxia [1 ]
机构：
[1] Shandong Univ, Sch Med, Dept Immunol, 44 Wenhua West Rd, Jinan 250012, Shandong, Peoples R China
[2] Shandong Univ, Sch Med, Dept Pathol, Jinan, Shandong, Peoples R China
[3] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA
[4] Yishui Cent Hosp Linyi City, Linyi, Shandong, Peoples R China
[5] Liaocheng Peoples Hosp, Dept Pediat, Liaocheng, Shandong, Peoples R China
来源：
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY | 2016年 / 64卷 / 09期
基金：
中国国家自然科学基金;
关键词：
diffuse large B-cell lymphoma; germinal center; non-Hodgkin's lymphoma; TNFAIP8L2; B-CELL LYMPHOMA; MOLECULAR SUBTYPES; HANS ALGORITHM; EXPRESSION; SUSCEPTIBILITY; POLYMORPHISMS; IMMUNITY; CANCER; ROLES; RISK;
D O I：
10.1369/0022155416662262
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Non-Hodgkin's lymphoma (NHL), which includes diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma, is a refractory malignant tumor originated from the lymphatic system. TNFAIP8L2 (TIPE2 or tumor necrosis-alpha-induced protein-8 like 2) is a negative regulator for inflammation and an inhibitor for carcinogenesis. However, whether TIPE2 plays a role in lymphomagenesis is unknown. In this study, we determined TIPE2 expression in NHL by immunohistochemistry and investigated its clinicopathological significance in DLBCL. We found that TIPE2 expression was upregulated in both DLBCL and peripheral T-cell lymphoma. But the expression of TIPE2 in T lymphomas was weaker than that in DLBCL. Interestingly, among DLBCL, TIPE2 expression was significantly stronger in the germinal center B-cell (GCB) type than in the non-GCB type. These results suggest that the expression of TIPE2 protein could be a predictor of better prognosis for DLBCL.
引用
收藏
页码：556 / 564
页数：9
相关论文
共 33 条
  • [1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    Alizadeh, AA
    Eisen, MB
    Davis, RE
    Ma, C
    Lossos, IS
    Rosenwald, A
    Boldrick, JG
    Sabet, H
    Tran, T
    Yu, X
    Powell, JI
    Yang, LM
    Marti, GE
    Moore, T
    Hudson, J
    Lu, LS
    Lewis, DB
    Tibshirani, R
    Sherlock, G
    Chan, WC
    Greiner, TC
    Weisenburger, DD
    Armitage, JO
    Warnke, R
    Levy, R
    Wilson, W
    Grever, MR
    Byrd, JC
    Botstein, D
    Brown, PO
    Staudt, LM
    [J]. NATURE, 2000, 403 (6769) : 503 - 511
  • [2] Immunohistochemical and Molecular Characteristics with Prognostic Significance in Diffuse Large B-Cell Lymphoma
    Bellas, Carmen
    Garcia, Diego
    Vicente, Yolanda
    Kilany, Linah
    Abraira, Victor
    Navarro, Belen
    Provencio, Mariano
    Martin, Paloma
    [J]. PLOS ONE, 2014, 9 (06):
  • [3] The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab
    Benesova, K.
    Forsterova, K.
    Votavova, H.
    Campr, V.
    Stritesky, J.
    Velenska, Z.
    Prochazka, B.
    Pytlik, R.
    Trneny, M.
    [J]. NEOPLASMA, 2013, 60 (01) : 68 - 73
  • [4] Human tumor necrosis factor (TNF)-alpha-induced protein 8-like 2 suppresses hepatocellular carcinoma metastasis through inhibiting Rac1
    Cao, Xuelei
    Zhang, Li
    Shi, Yongyu
    Sun, Yue
    Dai, Shen
    Guo, Chun
    Zhu, Faliang
    Wang, Qun
    Wang, Jianing
    Wang, Xiaoyan
    Chen, Youhai H.
    Zhang, Lining
    [J]. MOLECULAR CANCER, 2013, 12
  • [5] The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP
    Castillo, Jorge J.
    Beltran, Brady E.
    Song, Moo-Kon
    Ilic, Ivana
    Leppa, Sirpa
    Nurmi, Heidi
    Seki, Ritsuko
    Uccella, Silvia
    Li, Jun-Min
    Treaba, Diana O.
    Stachurski, Dariusz
    Butera, James N.
    [J]. LEUKEMIA RESEARCH, 2012, 36 (04) : 413 - 417
  • [6] A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy
    Choi, William W. L.
    Weisenburger, Dennis D.
    Greiner, Timothy C.
    Piris, Miguel A.
    Banham, Alison H.
    Delabie, Jan
    Braziel, Rita M.
    Geng, Huimin
    Iqbal, Javeed
    Lenz, Georg
    Vose, Julie M.
    Hans, Christine P.
    Fu, Kai
    Smith, Lynette M.
    Li, Min
    Liu, Zhongfeng
    Gascoyne, Randy D.
    Rosenwald, Andreas
    Ott, German
    Rimsza, Lisa M.
    Campo, Elias
    Jaffe, Elaine S.
    Jaye, David L.
    Staudt, Louis M.
    Chan, Wing C.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (17) : 5494 - 5502
  • [7] Genetic susceptibility to cancer - The role of polymorphisms in candidate genes
    Dong, Linda M.
    Potter, John D.
    White, Emily
    Ulrich, Cornelia M.
    Cardon, Lon R.
    Peters, Ulrike
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (20): : 2423 - 2436
  • [8] Altered immunity as a risk factor for non-Hodgkin lymphoma
    Grulich, Andrew E.
    Vajdic, Claire M.
    Cozen, Wendy
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (03) : 405 - 408
  • [9] The Anti-inflammatory TIPE2 Is an Inhibitor of the Oncogenic Ras
    Gus-Brautbar, Yael
    Johnson, Derek
    Zhang, Li
    Sun, Honghong
    Wang, Peng
    Zhang, Shirley
    Zhang, Lining
    Chen, Youhai H.
    [J]. MOLECULAR CELL, 2012, 45 (05) : 610 - 618
  • [10] Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
    Hans, CP
    Weisenburger, DD
    Greiner, TC
    Gascoyne, RD
    Delabie, J
    Ott, G
    Müller-Hermelink, HK
    Campo, E
    Braziel, RM
    Jaffe, ES
    Pan, ZG
    Farinha, P
    Smith, LM
    Falini, B
    Banham, AH
    Rosenwald, A
    Staudt, LM
    Connors, JM
    Armitage, JO
    Chan, WC
    [J]. BLOOD, 2004, 103 (01) : 275 - 282
1234